MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jagerschmidt, A.
Right arrow Articles by Noble, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jagerschmidt, A.
Right arrow Articles by Noble, F.

Vol. 53, Issue 5, 878-885, May 1998

Binding Sites and Transduction Process of the CholecystokininB Receptor: Involvement of Highly Conserved Aromatic Residues of the Transmembrane Domains Evidenced by Site-Directed Mutagenesis

Alexandre Jagerschmidt,1 Nathalie Guillaume, Bernard P. Roques, and Florence Noble

Département de Pharmacochimie Moléculaire et Structurale, Institut National de la Santé et de la Recherche Médicale U266-Centre National de la Recherche Scientifique, Unité de Recherche Associée D1500, Unité de Formation et de Recherche des Sciences Pharmaceutiques et Biologiques, 75270 Paris Cedex 06, France

The functional significance of the extracellular amino-terminal region and of three highly conserved aromatic residues present in the fifth (TM-V) and sixth (TM-VI) transmembrane domains of the rat cholecystokinin (CCK)B receptor, transfected in Cos-7 cells, was investigated by site-directed mutagenesis. The amino-terminal region of the CCKB receptor seemed to be weakly involved in CCK binding in that the affinities of CCK8 and selective agonists and antagonists were not modified by truncation of this region. Substitution of Phe347 in TM-VI with alanine produced a mutant receptor that displays the same affinity and selectivity as the wild-type receptor for agonists, but a slightly increased affinity for the selective CCKB antagonist L-365,260. However, the addition of saturating CCK8 concentrations to cells expressing this mutant did not result in the production of inositol phosphates, demonstrating the critical role of Phe347 in CCKB receptor to G protein coupling. Substitution of Phe227 with alanine was without effect on the affinities of CCKB ligands and on phosphoinositide turnover but modified the affinity of the CCKA antagonist L-364,718. Residue Trp351 located within the CCKB receptor TM-VI is involved in the binding of CCK8 and CCK4 and of the CCK4-based antagonist PD-134,308, as illustrated by the decreased affinities of these ligands in W351A mutant. The lower affinity for CCK8 observed with this mutated CCKB receptor accounts for the higher EC50 value for phosphotidylinositol hydrolysis. This study suggests that at least part of the binding site for the agonist is located inside the transmembrane domain of the CCKB receptor, partially overlapping that of antagonists, and gives new insights into the regions involved in the transduction process.

Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
M. Foucaud, I. G. Tikhonova, I. Langer, C. Escrieut, M. Dufresne, C. Seva, B. Maigret, and D. Fourmy
Partial Agonism, Neutral Antagonism, and Inverse Agonism at the Human Wild-Type and Constitutively Active Cholecystokinin-2 Receptors
Mol. Pharmacol., March 1, 2006; 69(3): 680 - 690.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
R. I. W. Osmond, A. Sheehan, R. Borowicz, E. Barnett, G. Harvey, C. Turner, A. Brown, M. F. Crouch, and A. R. Dyer
GPCR Screening via ERK 1/2: A Novel Platform for Screening G Protein-Coupled Receptors
J Biomol Screen, October 1, 2005; 10(7): 730 - 737.
[Abstract] [PDF]

Home page
 J. Biol. Chem.Home page
I. Langer, I. G. Tikhonova, M.-A. Travers, E. Archer-Lahlou, C. Escrieut, B. Maigret, and D. Fourmy
Evidence That Interspecies Polymorphism in the Human and Rat Cholecystokinin Receptor-2 Affects Structure of the Binding Site for the Endogenous Agonist Cholecystokinin
J. Biol. Chem., June 10, 2005; 280(23): 22198 - 22204.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
R. P. Millar, Z.-L. Lu, A. J. Pawson, C. A. Flanagan, K. Morgan, and S. R. Maudsley
Gonadotropin-Releasing Hormone Receptors
Endocr. Rev., April 1, 2004; 25(2): 235 - 275.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
C. Gales, M. Poirot, J. Taillefer, B. Maigret, J. Martinez, L. Moroder, C. Escrieut, L. Pradayrol, D. Fourmy, and S. Silvente-Poirot
Identification of Tyrosine 189 and Asparagine 358 of the Cholecystokinin 2 Receptor in Direct Interaction with the Crucial C-Terminal Amide of Cholecystokinin by Molecular Modeling, Site-Directed Mutagenesis, and Structure/Affinity Studies
Mol. Pharmacol., May 1, 2003; 63(5): 973 - 982.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Barroso, F. Richard, D. Nicolas-Etheve, J.-L. Reversat, J.-M. Bernassau, P. Kitabgi, and C. Labbe-Jullie
Identification of Residues Involved in Neurotensin Binding and Modeling of the Agonist Binding Site in Neurotensin Receptor 1
J. Biol. Chem., January 7, 2000; 275(1): 328 - 336.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
F. Noble, S. A. Wank, J. N. Crawley, J. Bradwejn, K. B. Seroogy, M. Hamon, and B. P. Roques
International Union of Pharmacology. XXI. Structure, Distribution, and Functions of Cholecystokinin Receptors
Pharmacol. Rev., December 1, 1999; 51(4): 745 - 781.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics